USANA Health Sciences Q2 2025 Earnings Report

USANA Health Sciences EPS Results

• Actual EPS: $0.74
• Consensus EPS: $0.54
• Beat/Miss: Beat by +$0.20
• One Year Ago EPS: N/A

USANA Health Sciences Revenue Results

• Actual Revenue: $235.85 million
• Expected Revenue: $225.20 million
• Beat/Miss: Beat by +$10.66 million
• YoY Revenue Growth: N/A

USANA Health Sciences Announcement Details

• Quarter: Q2 2025
• Date: 7/22/2025
• Time: After Market Closes
• Conference Call Date: Wednesday, July 23, 2025
• Conference Call Time: 11:00AM ET

USANA Health Sciences (NYSE:USNA) develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

USANA Health Sciences Q2 2025 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: USANA reported Q2 net sales growth of 11% and a 36% increase in adjusted EPS, exiting the quarter debt-free with $151 million in cash on the balance sheet.
• Positive Sentiment: The company launched a restructured direct-sales model, renaming “associates” as “brand partners” and rolling out an enhanced compensation plan, new business tools, and updated brand messaging to drive customer acquisition and partner engagement.
• Negative Sentiment: USANA expects short-term pressure on operating margins in Q3 due to meaningful investments related to its global convention, new product launches, and compensation plan enhancements.
• Positive Sentiment: Acquired businesses continued to deliver strong growth: HYA (Hyatt) posted solid top-line gains, highlighted by a Disney partnership, and RiseBar achieved double-digit sales growth with key retail partners.
• Neutral Sentiment: Management reaffirmed confidence in its fiscal 2025 outlook, citing the expected sustainable long-term impact of its strategic initiatives and ongoing integration synergies.

Presentation

[Operator]

Good morning, and welcome to the USANA Health Sciences Second Quarter Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to your host, Andrew Masuda, Director of Investor Relations. Thank you. You may begin.

[Andrew Masuda, Director - IR at USANA Health Sciences]

Thanks, Diego, and good morning, everyone. We appreciate you joining us to review our second quarter results. Today's conference call is being broadcast live via web webcast and can be accessed directly from our website at ir.usana.com. Shortly following the call, a replay will be available on our website. As a reminder, during the course of this conference call, management will make forward looking statements regarding future events or the future financial performance of our company.

[Andrew Masuda, Director - IR at USANA Health Sciences]

Those statements involve risks and uncertainties that could cause actual results to differ, perhaps materially, from the results projected in such forward looking statements. Examples of these statements include those regarding our strategies and outlook for fiscal year twenty twenty five, uncertainty related to the economic and operating environment around the world and our operations and financial results. We caution you that these statements should be considered in conjunction with disclosures, including specific risk factors and financial data contained in our most recent filings with the SEC. I'm joined by our President and CEO, Jim Brown our Chief Financial Officer, Doug Hacking our Chief Commercial Officer, Brent Nydig our Chief Operating Officer, Walter Note as well as other executives. Yesterday, after the market closed, we announced our second quarter results and posted our management commentary document on the company's website.

[Andrew Masuda, Director - IR at USANA Health Sciences]

We'll now hear brief remarks from Jim before opening the call for questions.

[Jim Brown, CEO & President at USANA Health Sciences]

Thank you, Andrew, and good morning, everyone. USANA delivered positive second quarter results consistent with our internal expectations. Consolidated net sales grew 11% year over year and adjusted earnings per share increased 36% from the prior year. Notably, we repaid our line of credit, which had carried a balance since our acquisition of Hyatt this past December and ended the quarter debt free with $151,000,000 in cash on the balance sheet. From an execution standpoint, this was a pivotal quarter for USANA as several strategic initiatives are in the process of being implemented.

[Jim Brown, CEO & President at USANA Health Sciences]

These initiatives are designed to strengthen our partnership with our brand partners whom we used to refer to as associates, accelerate product innovation, elevate the business opportunity and evolve our brand messaging. As I mentioned, we made a deliberate and intentional decision to change the terminology we use when referencing our sales leaders from associates to brand partners. Reflects a more strategic collaborative relationship and better represents the crucial role these individuals play in the sustainable long term growth of our business. If you recall, last year we reorganized our sales, marketing and communications departments in our direct selling business into one cohesive commercial team. This team is focused on delivering three fundamental benefits to our brand partners, best in class products, an income opportunity that is simple and motivates the entrepreneur with with a rewarding compensation plan and messaging that conveys product benefits and an income opportunity in a simple and compelling manner.

[Jim Brown, CEO & President at USANA Health Sciences]

This structure also positions us to improve the value proposition of USANA to our brand partners and customers by enhancing our already best in class products, become faster and more agile in developing and releasing new products, better understand specific brand partner and customer needs in each of our markets to deliver a more tailored experience, provide increased opportunities for brand partner engagement including events, meetings and reward trips and improve USANA's compensation offering for both part time and full time entrepreneurs. By making these changes, USANA will be at the forefront of today's evolving and competitive landscape for entrepreneurs. At a high level, our new opportunity entails an enhanced compensation plan, improved business building tools and updated brand story. Our updated compensation plan is a meaningful step forward in modernizing and simplifying our direct sales model to attract reward and reward new generations of entrepreneurs, as well as existing brand Some of these enhancements incentives have already been deployed and more incentives will roll out throughout the third quarter and fully launched by October providing USANA brand partners with an improved opportunity and supporting resources to drive customer acquisition and retention. The compensation enhancements also simplify the opportunity for brand partners to attract new generations of entrepreneurs by providing a better opportunity for new brand partners to earn compensation early in the journey, while simultaneously rewarding existing brand partners for activity that contributes to growth.

[Jim Brown, CEO & President at USANA Health Sciences]

Along with these enhancements, we've also launched new tools in our back office and mobile environment to make operating the USANA business easier than ever. For example, new functionalities will provide brand partners with data driven recommendations on how to grow their business and maximize their earnings. We have refined our brand by using clear language that highlights USANA's key differentiators and presents them in a compelling and easily repeatable format. Additionally, we continue to enhance our in person meeting strategy and our key regions plan to host more in person events that are upscaled and modern to attract new and younger generations. In conjunction with our new opportunity, we plan to announce several additional product launches along with various sales incentive offerings at our upcoming global convention next month in Salt Lake City.

[Jim Brown, CEO & President at USANA Health Sciences]

We expect approximately 3,500 of our best and most active brand partners from around the world to attend our global convention, and we plan to focus on recognizing their efforts and on actionable training to help them grow their businesses and to share more product. We're excited, optimistic and confident that these changes we are making to our direct sales model will be additive to customer growth, increase engagement and deliver long term sustainable growth. Moving on to our acquired businesses, we are encouraged by the recent performance of these entities, which provide USANA the ability to reach a broader demographic of health and wellness market, while providing diversification and strengthening USANA's financial profile. I'll start by sharing an update on our direct to consumer business, HYA. HYA had another strong quarter as year over year top line growth remains strong with improved profitability.

[Jim Brown, CEO & President at USANA Health Sciences]

Overall business activity levels remain encouraging as the Hyatt team recently launched a new partnership with Disney and rolled out special edition Disney Lion King and Disney Princesses branded multivitamin packs. We completed additional integration milestones during the quarter and as we move into the next phase of integration in the back half of the year, we will look to execute upon identified synergy and operational efficiency opportunities across logistics and manufacturing. We remain confident in Hyatt's growth outlook as the Hyatt team continues to execute its strategies to increase its market share in the children's health and wellness market by further growing and expanding its product offering, entering new distribution channels and expanding its geographic footprint into international markets. RiseBar, which was acquired in 2022, delivered strong double digit top line growth in the second quarter, driven by solid order activity with key retail partners. While still relatively small, we are encouraged by the recent momentum and the Rise Bar team remains confident and focused on expanding its product offerings, growing further with existing retail partners and landing new retail partners.

[Jim Brown, CEO & President at USANA Health Sciences]

Please note that we are investing meaningfully in the third quarter as we hold our global convention, introduce new and updated products and roll out exciting changes to our brand partner compensation plan. These investments, have been included in our annual guidance, are anticipated to create short term pressure on our operating margin during the third quarter. In closing, this is an exciting time for USANA as we take meaningful steps to modernize and evolve our direct sales business. Our acquired businesses are performing well and will further allow us to expand our reach in the health and wellness market. We remain confident in our fiscal twenty twenty five outlook and believe that successful execution of our strategies will deliver sustainable long term growth.

[Jim Brown, CEO & President at USANA Health Sciences]

With that, I'll now ask the operator to open the line for questions.

[Operator]

Thank you. And at this time, we will conduct our question and answer session. And our first question comes from Anthony Lebiedzinski with Sidoti and Company. Please state your question.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Hi, good morning everyone and thanks for taking the questions. So first, starting off with China. So your sales in your largest market outperformed our expectations even with a drop in active customers. So can you just provide more insight as to what's going on in China? What are you seeing there?

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

What happened in the quarter? And how should we think about the balance of the year, especially with the upcoming incentive program changes?

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

You bet. Anthony, it's Brent here. Thanks for the question. Were pleased with the performance of China throughout the quarter. Now if you recall, there were a lot of tariff activity that took place this year obviously and especially with our Chinese business.

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

We have about we have a little bit of exposure from cross border goods that are coming from The United States into China. And because of the tariff uncertainty, we did experience some increased buy up from our consumers in the market, which did attribute to some of the increase in performance throughout the quarter. But that tariff exposure outside of that, we were pleased with the performance from our brand partners. There still is a lot of optimism in the marketplace. We have a great management team there and there's a lot of cohesion amongst our brand partners.

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

So things are still performing well. There is economic uncertainty, which we're still saying very close paying close attention to. But outside of that, I think we're very optimistic about what the long term potential of that Chinese market is.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Got it. Yes. Thanks, Brent, for that. And then just looking at your overall active customer count, so as far as the overall decline that we saw in the second quarter, how much do you think was macro driven versus some of it was because of the upcoming changes in the compensation programs do you think?

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

I think there's a good portion that's attributable to the latter. Word did get out that we were going to be making adjustments to the incentive program and our sales teams around the world have been working for the last month in extensive communication with our brand partners to help them understand what the changes are. And naturally through that process there's always going to be some reservation about learning what that new program is, how that affects them. And so we did see a decrease to acquisition especially in the latter half of the quarter and that really impacts that active customer count. So that's something that we knew would happen and we're optimistic that that trend will turn around here in the third quarter as these new incentives continue to roll out.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Got it. Okay. So perhaps, I mean, you could just give us an example of maybe just walk us through an example of how a new brand partner would be compensated under the new incentive program compared to the legacy incentive program. Is this something you could just provide us kind of more details with?

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

Yes, sure. So we found through our research and through our data that especially with the current trends in the marketplace, it's becoming harder and harder for people to find success early on in their journey with USANA. And so that's something we specifically The wanted to address with these vast majority of our incentive program has remained unchanged. But there are some smaller elements of the plan that specifically relate to bonuses for behavior that we've made adjustments to. And we've brought some money forward in the beginning part of the journey of a new brand partner.

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

So before you might be able to a new brand partner would join, they would buy product for themselves and they would try to start selling product to other people. And oftentimes it would take them too long for them to earn their first commission check. And so with these enhancements, we've as I said, we brought some money forward in that journey to where you can immediately start earning income off every single sell that you make to a new customer or to a new brand partner. So that's a big adjustment that's been made. We've made some other tweaks to some of the other bonuses within the program.

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

But as a whole, our main goal is to drive acquisition through these enhancements to make it easier for people to join, make it easier for them to earn. And as they earn more quickly, they'll feel and know that USANA is successful, that this journey was the right choice for them and they'll want to stick with it longer.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

That's very helpful. And just circling back to the impact of tariffs, I know you touched on this a little bit here, but just overall thinking about the business as a whole not just China, but can you just can you speak to the impact of tariffs that you think you had on your business in the quarter and kind of how you're thinking about that for the balance of the year?

[Doug Hekking, CFO at USANA Health Sciences]

Yes. Anthony, this is Doug. Impact thus far has been fairly minimal. The operations and procurement team has done a really good job getting ahead of this with their sourcing strategy and really buying ahead of some of the potential exposure on the tariffs. We really haven't seen that much get put into place and this is on kind of primarily the importing of raws from market to market which is not a real big part regardless.

[Doug Hekking, CFO at USANA Health Sciences]

We still we see a lot of positioning from negotiating power not quite sure where that will land. And so I think we'll just keep evaluating and definitely put in a lot of effort. You can see that in our inventory build during the quarter and we'll update as we get more visibility to see what type of tariffs or trade policy type impact we see going forward.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Got you. Yes. Thanks, Doug. And then switching gears to Chaya. So as far as their second quarter sales results, we could see what you guys did here.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Can you give us a sort of a frame of reference as to how that compares to the year ago as far as the growth level there? Can you speak to that? Would be curious to get your thoughts on that.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

Hi. This is Walter, by the way, Anthony.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

I Hi.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

Mean, obviously, good growth. At the beginning of the year, that's when they started building up customers.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

Usually during the summer months, there's a little bit of a slowdown, which they've had and that was predicted. That's what we had in our models. And then as the year picks up, sales start picking up. So we've got we've had really good growth this year over last year, significant growth as you see in the numbers. But we expect August, especially with Princess coming out and the Disney and products come out, think that that's going to be a big deal for those guys.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Got you. Okay. And then just thinking about the integration, it sounds like you guys are pleased with how that's performed so far. Can you speak to the expected synergies and operational efficiencies that you may get from improved manufacturing and logistics? And I guess the second part would be also how are you guys thinking about expanding distribution of higher products beyond the core subscription business?

[Doug Hekking, CFO at USANA Health Sciences]

And maybe I'll take those in reverse role. I'll let Walter chime in here if he needs some clarification. I think right now we're going to just focus on the Hyatt products within Hyatt. We definitely see some opportunity down the road there and we'll evaluate that over some reasonable period of time. The group has been actively working on a host of operational initiatives and integration initiatives relative to getting Hyatt really prepped.

[Doug Hekking, CFO at USANA Health Sciences]

They got a great team and getting them ready to be part of a public company and we're making good progress on stuff probably a little bit earlier to be calling our shots as far as the savings and the uplift from there. But as start seeing those get realized we'll report on those and create some visibility.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

Yes. And I would say without really giving numbers yet, I would say that the benefit that we're giving them is it's our expertise in operations because we have big operations teams and they're really great at doing DTC. They're amazing at that.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

And we think they've been outsourcing their manufacturing of vitamins, powders, their 3PL that they've used all those different things that things that we do throughout the world, we've been helping them with. And we're I think you'll see in the next few quarters, you'll see you'll start seeing progress with those things that will be really good.

[Jim Brown, CEO & President at USANA Health Sciences]

Yes. This is Jim. This is we mentioned I mentioned in my comments at the beginning, but we are also helping them when it comes to potential international businesses and markets that they may go in. Nothing that would be immediate, but that would be something you see in 2026 or later. But again, our teams are helping them because we have really good people who have done this to get us in our 25 markets around the world.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Got it. Okay. Yeah, thanks for that. And nice to see you guys accelerating the share buyback so far this year. Just curious as to what your appetite is for additional share buybacks kind of going forward here?

[Doug Hekking, CFO at USANA Health Sciences]

We're going to be somewhat opportunistic. We really haven't commented and don't comment on prospective buyback, but this is a conversation we have every board meeting and we discuss it and kind of discuss the efficient kind of deployment and allocation of capital. And so that will be kind of top of mind and trying to maximize kind of the resources the company has and I think we feel very good about the strength of our balance sheet moving forward as well.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Got you. Okay. And then lastly for me, I mean, so obviously you're still busy integrating Hyatt, but longer term, what's your outlook about potential additional acquisition opportunities?

[Jim Brown, CEO & President at USANA Health Sciences]

Yes, just like Doug mentioned, we're looking at cash flow and cash management and we need to have some time to build, but we do have an active M and A department who are looking at opportunities. We'd love to find something out there again high end number two or something that fits into our direction from Health Products. But again, it's probably going to take a little bit of time to build up enough cash to find something that's appealing to us. But we do have that team out there looking. And you never know, something may come across their desk today and we'd have to react to it.

[Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC]

Understood. Well, you very much guys and best of luck.

[Jim Brown, CEO & President at USANA Health Sciences]

Thanks, Anthony.

[Doug Hekking, CFO at USANA Health Sciences]

Thanks, Anthony.

[Operator]

Thank you. And your next question comes from Ivan Feinseth with Tigress Financial Partners. Please state your question.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP]

Hi. Thank you for taking my question and congratulations on the results and ongoing progress.

[Jim Brown, CEO & President at USANA Health Sciences]

Appreciate it, Ivan.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP]

All right. So, in light of RFK's Make America Healthy initiative, especially targeting ingredients in products and especially for children, what kind of opportunities do you see that gives you a competitive advantage in where you are and what do you see as opportunities to follow this trend or get in on this trend going forward?

[Doug Hekking, CFO at USANA Health Sciences]

Ivan, this is Doug. I think really foundationally the way the company is run, we've been very deliberate, very intentional with how we develop and introduce products and what we feel really good about. It's really in our DNA. I think moving forward you'll see more of that and I think sometimes the environment fits there and I think it'll weed out some of the products that pop up day in and day out and kind of roll off and so I think that definitely provides some opportunity for us. Brent, don't know if anything else from kind of our product strategy approach.

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

Clearly, we're always taking a look at the external environment and trying to evaluate what we're doing internally to make sure that there's a good match there. I think the one thing that I'd say on this point Ivan is that we feel very confident in the internal team that we've developed both on the commercial side and within the R and D function. With the leadership of those two groups and with the teams that they have created that we can be more agile and more responsive to key trends that we see in the marketplace. We've always been strong at that but I think with the adjustments that we've made over the last year that we've become even more responsive. That's been a big part of the commercial team's restructure is that we want to make sure that we have a very robust product engine that is quick, that is responsive and that it's really responding to what's happening on the marketplace and giving our brand partners the right products that they need to succeed out in the marketplace.

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

So we're confident in our team's ability moving forward and we'll continue to pay attention to those trends.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

Ivan, this is Walter. You talked about kids health. I mean that's what Hyatt does and they're really poised for this. This is one of the reasons we were very excited about them when we saw them because they were beating all the trends in kids vitamins because they have really clean natural products and we really believe in what they sell. So they're going to do great.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP]

I think healthy habits begin early. So that is a good place to start with young people who can deviate down sometimes bad eating habits. But so I really like that your acquisition of Hyatt and the progress that they are making with them. Second, on the new brand partner concept, what kind of tools or infrastructure are you focusing on or building that help them as far as, let's say, on the technology side with CRM system as an example and on the social media side to provide brand partners with support and growing their business on using platforms like that. And is really creating an infrastructure that brings the brand partners that are choosing to make this a career to really have the business development tools to make it a successful career?

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

That's a great question. In addition to providing the right product to sell, the right incentive offering for them to be successful in the sale of that product, we think one of the third leg to that stool is making sure that they have the right tools so that they can be successful. Part of this compensation enhancement that we've rolled out this last quarter the end of last quarter and into the third quarter includes exactly what you're referencing which is an enhancement to the IT infrastructure or the tools that we're providing to our sellers. We're now trying to be more predictive and providing them with data driven predictions about who it is they should be working with within their network, who is opportunistic to make it to the next level. So we have provided a couple of new tools as part of this launch and there's some more tools that are going to be provided as the launch continues throughout the quarter.

[Brent Neidig, Chief Commercial Officer & MD - China at USANA Health Sciences]

We are evaluating some additional tools from a social media standpoint, how to ensure our brand partners are effective in delivering the message on social media. So we have one tool that's currently being trialed with a small group of brand partners. Assuming that goes well, we may try to expand that to other parts of the country and the world. But we're always opportunistic in that area and we'll continue to evaluate tools and provide our brand partners with the things that they need to be successful.

[Jim Brown, CEO & President at USANA Health Sciences]

Yes. Mean, this is Jim. Another area just to add on to what Brent is talking about is we're like a lot of companies getting more and more involved with AI and we see that as an opportunity to advance our tools for the future. We have a few tools right now that are being evaluated. Got to make sure we feel comfortable with how the AI functions with our data points.

[Jim Brown, CEO & President at USANA Health Sciences]

But I think it's going to be a big improvement over the next few quarters and years when it comes down to how we can help our brand partners make decisions on where to put their efforts.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP]

Thank you. Congratulations again and good luck going forward.

[Jim Brown, CEO & President at USANA Health Sciences]

Thank you. Appreciate it, Ivan.

[Operator]

Thank you. And there are no further questions at this time. So I'll hand the floor back to Andrew Masuda for closing remarks.

[Andrew Masuda, Director - IR at USANA Health Sciences]

Thanks for your questions and participation on today's conference call. If you have any remaining questions, please feel free to contact Investor Relations at (801) 954-7210.

[Operator]

Thank you. This concludes today's call. All parties may disconnect. Have a good day.

Participants

Executives

• Andrew Masuda, Director - IR
• Jim Brown, CEO & President
• Brent Neidig, Chief Commercial Officer & MD - China
• Doug Hekking, CFO
• Walter Noot, Chief Operating Officer

Analysts

• Anthony Lebiedzinski, Senior Equity Analyst - Specialty Retail/Consumer at Sidoti & Company, LLC
• Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP